News

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

Alan Franklin, MD, PhD, FASRS, spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

The study helped identify predisposing factors for severe SANS in astronauts.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

Nikoloz Labauri, MD, FVRS, founder of DAVINCI Eye Clinic in Tbilisi, Georgia, discusses his presentation, "Suspensory Macular Buckling for Myopic Traction Maculopathy" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.

The retrospective study was conducted at King Khaled Eye Specialist Hospital (KKESH), in Riyadh, Saudi Arabia, to review the impact of the COVID-19 pandemic on the training program by comparing the years 2018 and 2019 before the pandemic to 2020 and 2021 after the pandemic.

Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.

Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of geographic atrophy in dry age-related macular degeneration" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.

Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.

A few studies have highlighted the differences between healthcare professionals with CVD and those with normal color vision.

Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.

Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

According to the company, its implantable miniature telescope is a Galilean intraocular telescope designed to improve visual acuity and quality of life for patients with late-stage AMD.

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

The organization is poised to lobby for an indefinite extension of Medicare reimbursement for telemedicine services and fight the December 31, 2024, sunset date when Medicare plans to cease reimbursement for these services.

Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

Yasha Modi, MD, spoke with Modern Retina about the ASRS 2024: The DAVIO phase 2 trial and upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.

Jordana Fein, MD, MS, spoke with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.

Riaz Qureshi, PhD, explains the effects of spin sneaking into systematic reviews and ways the scientific community can better identify it to improve the validity.